Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CJ-30060 in Healthy Males
NCT03639493Phase 1Completed
- Sponsor
- HK inno.N Corporation
- Start
- Apr 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CJ-30060 in hypertension (HTN) and hyperlipidemia (2 arms), sponsored by HK inno.N Corporation. Primary endpoints: Maximum Plasma Concentration (Cmax) of Amlodipine, Maximum Plasma Concentration (Cmax) of Valsartan and 4 more. Started Apr 2018; status: completed.
02
Drugs
CJ-30060
03
Conditions
hypertension (HTN)hyperlipidemia
Beyond the preview
Go deeper on NCT03639493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639493.